Stemline Therapeutics IPO watch: The biopharmaceutical company filed the amendment to Form S-1 with the Securities and Exchange Commission on June 19, 2012. According to the latest regulatory filing, the company intends to list its common stock on the NASDAQ Global Market under the symbol “STML.” The company has not disclosed the number of shares will be sold in the public offering and the Stemline Therapeutics IPO price.
Stemline Therapeutics, Inc., founded in 2003, is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk. The company is currently developing two clinical-stage product candidates, SL-401 and SL-701.
The net procceds from the Stemline Therapeutics IPO will be used for clinical development of SL-401 and SL-701 and other general corporate purposes.
RBC Capital Markets, Oppenheimer & Co. and JMP Securities are acting as underwriters of the Stemline Therapeutics IPO.